Product Information
SELEGILINE HCL 5 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.7563 per EA under NDC 16571065906. Its NADAC has been published 350 times since Jan 22, 2020.
FDA first approved this application on Apr 2, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571065906
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SELEGILINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206803FDA Approved
4/2/2019
TE Code
AB
On Market Since
4/2/2019
Pharmacological Classes
Price Statistics
The NADAC for SELEGILINE HCL 5 MG CAPSULE has been published 350 times since Jan 22, 2020, and over the history we have for it it has declined 30.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7563 per EA |
|---|---|
| All-time high | $1.3924 (Aug 12, 2020) |
| All-time low | $0.4117 (May 22, 2024) |
| 52-week high | $0.7563 |
| 52-week low | $0.6053 |
| Median price | $0.8546 |
| Average price | $0.8566 |
| Largest weekly change | +51.1% (Nov 22, 2023) |
| Weeks tracked | 350 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Selegiline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Monoamine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SELEGILINE HCL 5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for SELEGILINE HCL 5 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.7563 per EA (NDC 16571065906), effective Sep 30, 2026.
How has the price of SELEGILINE HCL 5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for SELEGILINE HCL 5 MG CAPSULE has declined 30.0%. It has been tracked across 350 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for SELEGILINE HCL 5 MG CAPSULE?
Since Jan 22, 2020, the NADAC for SELEGILINE HCL 5 MG CAPSULE has ranged from a low of $0.4117 (May 22, 2024) to a high of $1.3924 (Aug 12, 2020), with a median of $0.8546 per EA.
Are there cheaper alternatives to SELEGILINE HCL 5 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SELEGILINE HCL 5 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures SELEGILINE HCL 5 MG CAPSULE?
SELEGILINE HCL 5 MG CAPSULE (NDC 16571065906) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.